Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation [PDF]
New England Journal of Medicine, 2001 BACKGROUND Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in
Salim Yusuf +6 more
semanticscholar +7 more sources
Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? [PDF]
European Journal of Medical Research, 2010 Background Dual therapy with aspirin and clopidogrel increases the risk of gastrointestinal bleeding. Therefore, co-therapy with a proton pump inhibitor (PPI) is recommended by most guidelines.
Kenngott S +6 more
doaj +5 more sources
The Role of Clopidogrel in 2020: A Reappraisal
Cardiovascular Therapeutics, 2020 Antiplatelet therapy is the mainstay of treatment and secondary prevention of cardiovascular disease (CVD), including acute coronary syndrome (ACS), transient ischemic attack (TIA) or minor stroke, and peripheral artery disease (PAD).
Giuseppe Patti +3 more
doaj +2 more sources
Clopidogrel Bisulfate (Profiles of Drugs Substances, Excipients and Related Methodology) [PDF]
, 2010 Clopidogrel contains a center of dissymmetry, and hence is capable of being resolved into its two mirror image compounds. It has been found that only the (S)-enantiomer, which corresponds to the dextrorotatory form, has antithrombotic activity and that ...
Gunawan Indrayanto +3 more
core +5 more sources
Clopidogrel Management in Abdominal Surgery: A Comparison of Perioperative Bleeding Risks with Low-Molecular-Weight Heparin Bridging, No-Bridging and Clopidogrel Continuation Strategies. [PDF]
Clin Appl Thromb HemostClopidogrel is usually discontinued 5–7 days before elective surgery to reduce the risk of bleeding. However, the perioperative safety of patients receiving low-molecular-weight heparin (LMWH) bridging therapy or continuing clopidogrel therapy remains ...
Hu B, Chen J, Han S, Dai Z, Gao J.
europepmc +2 more sources
Frontiers in Neurology, 2021 Background: The factors associated with clopidogrel resistance in patients with stroke recurrence receiving single or dual antiplatelet treatment (SAPT or DAPT) may differ.
Hyun Goo Kang +4 more
doaj +1 more source
Indonesian Biomedical Journal, 2021 BACKGROUND: Light transmission aggregometry (LTA) and VerifyNow is commonly used to measure platelet responsiveness to clopidogrel. This study aimed to compare the results of LTA and VerifyNow P2Y12 assay for assessing the clopidogrel resistance in ...
Astuti Giantini +11 more
doaj +1 more source
Clinical pharmacology and therapy, 2022 CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition ...
Craig R. Lee +16 more
semanticscholar +1 more source
Ilaprazole and Clopidogrel Resistance in Acute Stroke Patients
Biomedicines, 2022 Clopidogrel, an antiplatelet agent used for secondary prevention of cerebrovascular diseases, is often taken with proton pump inhibitors (PPIs). Generally, the combined use of clopidogrel and PPIs causes adverse drug–drug interactions.
In Hwan Lim +3 more
doaj +1 more source
Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis. [PDF]
PLoS ONE, 2018 The clinical significance of the laboratory-based phenomenon of clopidogrel hypo-responsiveness and platelet reactivity associated with acute myocardial infarction, despite chronic clopidogrel therapy, is largely unknown.
Ehud Regev +6 more
doaj +1 more source